Related Experiment Videos
Ciclopirox nail lacquer and podiatric practice
1Department of Medicine, Sunnybrook and Women's College Health Sciences Center (Sunnybrook Site), Toronto, Ontario, Canada. agupta@execulink.com
Journal of the American Podiatric Medical Association
|December 7, 2000
Summary
Ciclopirox 8% nail lacquer is a new FDA-approved topical treatment for mild-to-moderate onychomycosis. Nail debridement is crucial for managing fungal nail infections, whether treated with oral medications or topical ciclopirox.
Area of Science:
- Dermatology
- Mycology
- Pharmacology
Background:
- Onychomycosis, a fungal nail infection, has traditionally been treated with oral antifungal medications.
- The US Food and Drug Administration (FDA) has approved ciclopirox 8% nail lacquer for mild-to-moderate cases not affecting the lunula.
Observation:
- Topical ciclopirox lacquer requires monthly nail debridement by a healthcare professional.
- Nail debridement is a key component in managing onychomycosis, reducing fungal load and symptoms.
Findings:
- Ciclopirox 8% nail lacquer offers a new topical treatment option for onychomycosis.
- The role and reimbursement of nail debridement in conjunction with topical or oral treatments are important considerations.
Implications:
- Podiatrists face choices regarding treatment protocols for onychomycosis, including oral agents, topical ciclopirox, or combination therapies.
- The integration of nail debridement into treatment plans for fungal nail infections is highlighted with the advent of new topical therapies.